Recursion cuts workforce ~20%, extends cash runway to Q4 2027; $11M severance charges

RECURSION PHARMACEUTICALS, INC.

Workforce reduction of ~20%; expects ~$11M in severance and related costs in 2025.
Cash runway now projected into Q4 2027; cash burn guidance <$450M in 2025, <$390M in 2026.
Expects Q2 2025 cash above $500M; includes $28M R&D tax credit and >$100M potential milestone inflows by end 2026.
Reduction part of streamlined operating strategy and post-integration transitions.

item 2.05item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.